KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced its recently expanded, state-of-the-art Geneva mammalian cell manufacturing facility has obtained a Swissmedic regulatory es...
Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics and Manufacturing of Difficult-to-Express Biologics
The KBI Biopharma agreement provides that KBI Biopharma will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial...
Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
Symphogen has developed unique technologies for the controlled, reproducible production of highly characterized MAb mixtures manufactured in a single batch.